Back to today’s briefing

Story perspectives

Phio Pharmaceuticals Advances Skin Cancer Trial with Safety Boost

6/27/2025

42 9

Summary

Story summary

Phio Pharmaceuticals received an encouraging nod from the Safety Monitoring Committee to increase doses in its Phase 1b trial of PH-762, a promising skin cancer treatment. Patients battling cutaneous squamous cell carcinoma reported a reassuring safety profile, with no serious side effects. Enrollment is set to wrap up by Q3 2025, bringing hope to many.

1 of 1

Story summary

Phio Pharmaceuticals received an encouraging nod from the Safety Monitoring Committee to increase doses in its Phase 1b trial of PH-762, a promising skin cancer treatment. Patients battling cutaneous squamous cell carcinoma reported a reassuring safety profile, with no serious side effects. Enrollment is set to wrap up by Q3 2025, bringing hope to many.